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Two parallel phase II trials in adults with hematologic malignancies demonstrated comparable survival after
reduced-intensity conditioning and transplantation of either 2 HLA-mismatched umbilical cord blood (UCB)
units or bone marrow from HLA-haploidentical relatives. Donor choice is often subject to physician practice
and institutional preference. Despite clear preliminary evidence of equipoise between HLA-haploidentical
related donor and double unrelated donor UCB transplantation, the actual prospect of being randomized
between these 2 very different donor sources is daunting to patients and their treating physicians alike.
Under these circumstances, it is challenging to conduct a phase III randomized trial in which patients are
assigned to the UCB or haploidentical bone marrow arms. Therefore, we aimed to provide an evidence-based
review and recommendations for selecting donors for adults without an HLA-matched sibling or an HLA-
matched adult unrelated donor.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
A 58-year-old man with de novo acute myeloid leukemia
(French-American-British subtype: M2) is enrolled in the
Southwest Oncology Group trial 1203. Cytogenetic tests are
consistent with normal karyotype and molecular tests
consistent with mutated NPM1 (gene) and FLT3-ITD (internal
tandem duplications of FLT3 gene) positive. The patient un-
derwent induction therapy and achieved ﬁrst complete
remission. A donor search was initiated soon after diagnosis,
because the patient and his sibling were fully HLA mis-
matched. Preliminary search of the adult unrelated donor
registries suggested the patient lacked unrelated adult do-
nors who are likely to be HLA matched at HLA-A, -B, -C, and
-DRB1. However, several potential mismatched related and
mismatched unrelated adult donors and umbilical cord blood
(UCB) units were identiﬁed. Potential alternative donor op-
tions included (1) the recipient’s son, aged 23 years andedgments on page 1491.
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14.05.015partially HLA matched (HLA haploidentical) to the recipient;
(2) an unrelated adult donor, aged 35 years, mismatched to
the recipient at the allele level at HLA-A with a permissive
mismatch at HLA-DPB1 (this unrelated donor was medically
ﬁt and able to donate within 8 weeks); and (3) 3 UCB units:
unit 1 has a single mismatch at HLA-A to the recipient with a
total nucleated cell (TNC) dose of 3.1  107/kg; unit 2 has a
single mismatch at HLA-B with a TNC dose of 3.5  107/kg;
and unit 3 is has a single mismatch at each of HLA-A and
-DRB1 with a TNC dose of 4.1  107/kg.
The treating physician and the patient decided to proceed
with allogeneic hematopoietic cell transplantation and are
currently engaged in discussions as to the best alternative
donor available. They are particularly interested in a phase III
clinical trial conducted by the Blood and Marrow Transplant
Clinical Trials Network (BMT CTN 1101; NCT0159778) that is
open for enrollment. In this trial, using the platform as
designed for the earlier parallel phase II trials (BMT CTN 0603
and BMT CTN 0604) [1], patients are randomized to either
HLA-haploidentical donors or 2 UCB units. The phase II trials
(BMT CTN 0603 and BMT CTN 0604) tested reduced-intensity
conditioning regimens of similar intensity for adults with
hematologic malignancy; BMT CTN 0603 used bone marrowTransplantation.
Table 1




Blood BMT CTN 0604
Haploidentical Bone
Marrow BMT CTN 0603
Nonrelapse mortality 28% (95% CI, 15%-41%) 8% (95% CI, .4%-16%)
Relapse 36% (95% CI, 23%-50%) 58% (95% CI, 43%-72%)
Progression-free
survival
36% (95% CI, 23%-49%) 35% (95% CI, 21%-48%)
Overall survival 39% (95% CI, 26%-53%) 54% (95% CI, 39%-67%)
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CTN 0604 used mismatched UCB grafts (co-infusion of 2 UCB
units). The 1-year overall and progression-free survival rates
after haplo-BM transplantation was 62% (95% conﬁdence
interval [CI], 44% to 76%) and 48% (95% CI, 32% to 62%),
respectively [1]. The corresponding probabilities after mis-
matched UCB transplantation were 54% (95% CI, 38% to 67%)
and 46% (95% CI, 31% to 60%) [1].
Thirty-four of 50 subjects enrolled in BMT CTN 0603 and
29 of 50 subjects enrolled in BMT CTN 0604 were alive at time
of publication of the above report in 2011 [1]. Surviving sub-
jects were followed up in 2013: 27 of 34 subjects in BMT CTN
0603 and 20 of 29 subjects in BMT CTN 0604 were alive in
2013. The median follow-up of surviving subjects enrolled in
BMT CTN 0603 and 0604 was 3 years (range, 2 to 4). The 3-
year overall and progression-free survival rates after haplo-
BM transplantation were 54% (95% CI, 39% to 67%) and 35%
(95% CI, 21% to 48%), respectively (Table 1, Figure 1A,B). The
corresponding probabilities after mismatched UCB trans-
plantationwere 39% (95% CI, 26% to 53%) and 36% (95% CI, 23%
to 49%) (Table 1, Figure 1C,D). The pattern of treatment failureFigure 1. The 3-year probability of (A) overall survival after HLA-haploidentical bone
bone marrow transplantation, (C) overall survival after double UCB transplantation, adiffered between the 2 donor sources (Table 1, Figure 2A-D).
Relapse rates were high and nonrelapse mortality rates low
after haplo-BM transplantation. In contrast, relapse and non-
relapse mortality rates were modestly high after mismatched
UCB transplantation. There were no reported cases of graft
failure with extended follow-up after haplo-BM and UCB
transplantation.
Despite clear preliminary evidence of equipoise between
HLA-haploidentical related donor and double unrelated
donor UCB transplantation, the actual prospect of being
randomized to different donor sources has proved to be a
challenge. To our knowledge, differing patterns of treatment
failure in BMT CTN 0603 and 0604 have not been cited as an
inhibitory factor for randomization. For patients referred to
the larger centers known for their expertise for UCB or
haploidentical transplantation, this amounts to selecting the
donor source based on center expertise. On the other hand,
physician bias relates to their perceived knowledge on the
optimal alternative donor for their patients without an HLA-
matched sibling or adult unrelated donor. Consequently,
accrual to the trial has ramped up slowly; it has taken over a
year from opening the trial to achieve projected quarterly
accruals. Therefore, in this report, we present guidelines for
donor selection based onpublished current and relevant data.
DONOR SOURCES OTHER THAN HLA-MATCHED SIBLINGS
FOR HEMATOPOIETIC CELL TRANSPLANTATION
When an HLA-matched sibling is not available or not
suitable to donate, alternative donors may be considered if
the patient is likely to beneﬁt from allogeneic trans-
plantation. Alternative donor sources include HLA-matched
or mismatched adult unrelated donors, unrelated UCB, and
mismatched family members (haploidentical donor).marrow transplantation, (B) progression-free survival after HLA-haploidentical
nd (D) progression-free survival after double UCB transplantation.
Figure 2. The 3-year probability of (A) nonrelapse mortality after HLA-haploidentical bone marrow transplantation, (B) relapse after HLA-haploidentical bone
marrow transplantation, (C) nonrelapse mortality after double UCB transplantation, and (D) relapse after double UCB transplantation.
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Better supportive care, including the selection of unre-
lated adult donors who are more closely HLA matched to
their recipients, have improved survival after allogeneic
transplantation for hematologic malignancy. Reports support
the general concept of a direct association between the
number of donor-recipient HLA mismatches and mortality
risks. Based on available literature, a fully matched donor is
one who is HLA matched to the recipient at the allele level at
HLA-A, -B, -C, and -DRB1 [2-4]. Although some would sup-
port including HLA-match status at the HLA-DQ locus, in
their deﬁnition of a “suitably HLA-matched unrelated donor,”
it is important to note that over 95% of donorerecipient pairs
matched at the allele level at HLA-A, -B, -C, and -DRB1 are
also matched at HLA-DQ and an isolated mismatch at the
HLA-DQ locus does not have an adverse effect on survival [4].
Other frequently asked questions include whether HLA-
match requirements differ when selecting peripheral blood
progenitor cells (PBPCs) or with reduced-intensity transplant
conditioning regimens. PBPC grafts differ from BM in that the
former contain substantially more cells including CD3þ and
CD34þ cells, which might inﬂuence the effects of HLA
matching. Unrelated PBPC transplantations mismatched at a
single HLA locus for HLA-A, -B, -C, or -DRB1 were associated
with higher mortality compared with transplantations
matched at HLA-A, -B, -C, and -DRB1 [5] and consistent with
that reported for BM grafts [4]. As seen with BM trans-
plantations, an isolated mismatch at the HLA-DQ locus was
not associated with higher mortality risks. With the increase
in numbers of reduced-intensity conditioning regimen
transplantations for hematologic malignancy, it is timely to
explore whether HLA match is associated with survival. In a
recent study that explored matching at HLA-A, -B, -C, and
-DRB1 in 2500 donorerecipient pairs, a single locus HLAmismatch was associated with higher mortality [6]. It
is noteworthy that most reduced-intensity conditioning
regimen transplantations are matched (only 21% were
mismatched at a single HLA locus), and matching at HLA-DQ
was not considered in that report. Taken together, the gen-
eral concept of a direct association between donorerecipient
HLA match and survival after unrelated adult donor trans-
plantation holds true for BM and PBPC grafts and for mye-
loablative and reduced-intensity conditioning regimens.
HLA-A, -B, -C, and -DRB1 are the high expressing alleles.
However, there are several low expressing alleles, and
matching between donors and recipients does not routinely
consider them. Two recent reports explored the effects of
matching at low expression alleles. In the ﬁrst, Fleischhauer
and colleagues [7] considered the effects of matching at
HLA-DPB1, grouped as matched, permissive, or nonpermis-
sivemismatch based onTcell epitopematching. In that study,
HLA match was deﬁned as donorerecipient pairs matched at
the allele level at HLA-A, -B, -C, -DRB1, and -DQB1. On the one
hand, there were no signiﬁcant differences in mortality risks
betweenHLA-matched transplantations and transplantations
with permissive mismatch at HLA-DPB1 locus. On the
other hand, nonpermissive mismatch at HLA-DPB1 locus
was associated with higher mortality for matched and
single HLA-locus mismatch transplantations. Interestingly,
a permissive mismatch at the HLA-DPB1 locus was rather
well tolerated with no signiﬁcant differences in mortality
risks between HLA-matched transplantations and single
HLA-locus mismatched transplantations. The data support
avoiding a nonpermissive mismatch at the HLA-DPB1 locus,
resulting in better survival. The second report explored the
effect of multiplemismatches at HLA-DP, -DQ, and -DRB3/4/5
[8]. Theﬁndings support the general concept thatmatching at
the low expression alleles can be ignored when donors and
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other hand, in the presence of a single HLA locusmismatch at
anyof thehighexpressingalleles, 3 ormoremismatches at the
low expressing alleles is associated with high mortality.
Therefore, in the absence of an unrelated donor matched at
HLA-A, -B, -C, and -DRB1, it is important to considermatching
at HLA-DP, DQ, and DRB3/4/5 [9].
Availability of suitably HLA-matched adult unrelated donors
Unfortunately, HLA-matched unrelated donors are not
available for all patients even with large unrelated adult
donor registries because the polymorphism of HLA genes is
extremely high and allelic variation is population-speciﬁc
[10,11]. The Bioinformatics Division of the National Marrow
Donor Program, using their donor registry of volunteer
donors, recently built mathematical models to predict the
likelihood of identifying a suitable adult donor for patients in
the United States and considering race/ethnic groups [12].
That report [12] suggested the ethnic and racial group of the
patient inﬂuences the likelihood of identifying a suitable
donor. An HLA-matched unrelated adult donor can be iden-
tiﬁed without difﬁculty for patients with common HLA
genotypes. Consequently, about 75% of Whites of European
descent will ﬁnd a fully HLA-matched adult donor and
another 20% will ﬁnd a donor who is mismatched at a single
HLA locus (HLA-A, -B, -C, or -DRB1). For persons of other
races and/or ethnicities, the likelihood of identifying a fully
HLA-matched adult donor is substantially lower and ranges
from 15% to 50%. If a single HLA mismatch (at HLA-A, -B, -C,
or -DRB1) can be tolerated, almost all persons will be able to
identify an adult donor. It is noteworthy that the mathe-
matical model did not consider matching at the low
expression alleles, and the likelihood of identifying suitably
mismatched unrelated adult donors (ie, tolerating a single
HLA mismatch at a high expressing alleles [HLA-A, -B, -C, or
DRB1] and fewer than 3mismatches at low expressing alleles
[HLA-DP, -DQ, -DR3/4/5]) could be even lower than what is
predicted using the current mathematical model, which only
considered the high expression loci. Clearly, survival after
adult unrelated donor transplantation mismatched at a sin-
gle HLA locus is lower than that after matched unrelated
donor transplantation. Although selecting a mismatched
adult unrelated donor may be acceptable to several treating
physicians, others favor HLA-haploidentical relatives or UCB
units.
Further, the time from diagnosis to transplantation for
hematologic malignancy adversely affects patient outcomes,
and any delay incurred in procuring an adult donor unrelated
graft is an obstacle to the timing of allogeneic transplantation
[13,14]. Potential adult unrelated or related donors have to be
medically ﬁt and available to donate. Although a relative is
oftenavailable todonate andUCBunits readilyavailable froma
Cord Blood Bank, the average time from identiﬁcation of an
adult unrelated donor to transplantation is approximately
7 weeks. For patients with high-risk hematologic malignancy,
7 weeks could be too long a waiting period. The other impor-
tant factor to consider is donor attrition with respect to the
unrelated adult donor. Attrition rates vary; higher attrition
rates are associated with large volume donor centers, donors
residing in high population urban areas with large minority,
and less stable populations [15]. Additionally, intrinsic
commitment to donation, more realistic expectations, fewer
medical concerns, and greater contact with the donor center
were all associated with lower attrition [16]. Attrition rates
among family donors is minimal and for UCB units, none.Taken together, for patients with common HLA pheno-
types, a suitably matched adult donor can usually be
identiﬁed on the ﬁrst match run. If one is not able to identify
a suitably matched adult donor in a worldwide search
(19 million donors), it is unlikely that newly recruited donors
will match the patient in a timely manner [12]. Thus,
although every attempt must be made to identify the best
HLA-matched donor, delaying transplantation because such
a donor is not immediately available is not advisable. Under
these circumstances it is recommended that alternative
treatment options be evaluated, including lowering
HLA-match requirements or using another unrelated graft
source such as UCB or partially matched family members.
The high cost of extensive HLA typing must also be consid-
ered. Enlisting the assistance of an HLA expert can help
maximize available resources by focusing selection of donors
for screening to those most likely to match the patient.
Unrelated UCB
UCB units are increasingly used as an alternative donor/
graft for unrelated donor transplantation in adults. Although
most UCB transplantations have been performed in children
and adolescents, increasing numbers are now being per-
formed in adults and account for about 10% of allogeneic
transplants in adults. UCB units are readily available, and
generally HLA-match requirements are less stringent than
that for the adult grafts (BM or PBPCs), making this an
attractive alternative option in the absence of a suitably
HLA-matched related or unrelated adult donor.
Several reports from transplant registries and single
institutions have retrospectively compared outcomes after
HLA-matched and mismatched adult unrelated donor trans-
plantation to that after UCB transplantation, including
infusion of 2 UCB units, with comparable overall and
leukemia-free survival [17-19]. All these reports included
patients in all disease states at transplantation (ie, ﬁrst or
second complete remission and in relapse at transplantation).
It is plausible ﬁndings may differ in selected populations. In a
recent report [20], older patients (aged 50 years or older) with
acute myeloid leukemia in ﬁrst complete remission had
signiﬁcantly higher leukemia-free and overall survival after
HLA-matched adult donor transplantation compared with
either mismatched adult donor or UCB transplantation.
Nonrelapse mortality was high after both mismatched adult
donor and UCB transplantation, accounting for the observed
differences in leukemia-free and overall survival after
matched and mismatched adult donor or UCB trans-
plantation. It is noteworthy that these reports considered
matching at HLA-A, -B, -C, and -DRB1 at the allele level, and
matching at the low expression alleles (for the mismatched
adult unrelated donor transplants) was not considered.
A major limitation when considering UCB trans-
plantation, regardless of the patient’s age, is the high
nonrelapse mortality risk. A substantial proportion of adults
in the United States are unable to ﬁnd a single UCB unit with
adequate TNC counts, and several strategies are used to
increase the TNC dose delivered. These include the infusion
of 2 UCB units [1,21,22], infusion of UCB unit or units with
CD34-selected hematopoietic progenitor cells from an
HLA-haploidentical relative [23,24], or infusion of ex vivo
expanded UCB units with 2 nonmanipulated UCB units
[25,26]. These strategies have resulted inmarkedly improved
hematopoietic recovery and in some cases achieving recov-
ery times comparable with that after transplantation of
PBPCs. To our knowledge, none of these early trials with
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poietic progenitor cells from an HLA-haploidentical donor
together with a UCB unit has demonstrated a survival
advantage compared with infusion of 2 unmanipulated UCB
units. Only with longer follow-up of patients treated with
expanded UCB units and the conduct of comparative studies
with conventional unrelated adult donors can we determine
whether these strategies may be translated to everyday
clinical practice and, importantly, whether there is a longer-
term survival advantage with this approach as compared
with conventional UCB transplants (ie, infusion of 1 or 2
adequately dosed UCB units).
An important difference when selecting volunteer unre-
lated adult donors and UCB units is the criteria for
HLA-matching donors to recipients. Unrelated adult donors
are selected to be closely HLA matched to recipients and
consider matching at HLA-A, -B, -C, and -DRB1 at the allele
level at the very least [2-4], whereas UCB units are selected
using lower resolution HLA typing (antigen level) for HLA-A
and -B and at the allele level for HLA-DRB1; HLA-C is not
typically considered. However, 2 recent publications
suggested considering allele-level HLA-matching, including
matching at the HLA-C, when selecting UCB units leads to
better hematopoietic recovery and lower nonrelapse mor-
tality [27,28]. It is important to note that the ﬁndings of these
reports are applicable to the selection of single UCB units for
transplantation of patients with hematologic malignancy.
The role of better HLA-matched units in the setting of double
UCB transplantation (infusion of 2 UCB units) is not known.
In the setting of adult unrelated donor transplantations,
differences in mortality risks are negligible when comparing
transplantations mismatched at 2 or more HLA loci. Because
most UCB transplantations in adults are already mismatched
at 2 HLA loci at the lower resolution, only with larger
numbers of better-matched UCB transplants can we begin to
study the role of HLA matching in the setting of double UCB
transplantation.
Haploidentical Donors
Almost all patients will have at least 1 haploidentical
relative, and this represents a valid donor source for those
who may beneﬁt from allogeneic hematopoietic trans-
plantation. Potential advantages of haploidentical donors
include immediate availability and ﬂexible management of
graft procurement, avoiding the monetary burden associated
with an unrelated donor search, and the availability of the
donor for post-transplantation cellular therapy. Early studies
of HLA-haploidentical stem cell transplantation clearly
showed worsening outcomes with increasing HLA disparity
between donor and recipient [29,30]. These studies generally
used serologic rather than molecular typing and so the
extent of mismatch may have been underestimated.
Although 1 HLA antigen-mismatched transplants produced
outcomes comparable with transplants from HLA-matched
siblings, 2 or 3 antigen-mismatched transplants were asso-
ciated with high incidences of severe graft-versus-host dis-
ease (GVHD), nonrelapse mortality, and poor survival [29].
Increasing HLA mismatch between donor and recipient may
be associated with a decreased risk of leukemia relapse [31],
especially among patients with poor-risk hematologic
malignancies, but this beneﬁt of mismatching is more than
offset by the higher incidence of nonrelapse mortality [30].
Increasing HLA disparity between donor and recipient was
associated with an increased risk of graft failure, which was
also more common among recipients who had antibodiesagainst donor HLAmolecules [32]. Taken together, the results
of these early studies in HLA-haploidentical stem cell trans-
plantation led to the preferential selection of donors with the
least degree of HLA mismatch and the use of donor-speciﬁc
antibody testing to exclude donors whose grafts were more
likely to be rejected.
Several groups demonstrated that graft failure, GVHD,
and nonrelapse mortality rates were acceptable through a
variety of strategies that targeted in vivo or ex vivo graft
engineering methods. The Perugia group used in vivo graft
engineering methods to selectively deplete T cells that result
in very low GVHD rates but high nonrelapse mortality rates
[33]. More recently, they augmented their strategy with
infusion of selective T cell and natural killer (NK) cell pop-
ulations as a means of introducing antiviral activity to reduce
nonrelapse mortality [34]. Although successful, the approach
is not used widely.
The effect of HLA mismatching between donor and
recipient has been revisited in the recent era of improved
GVHD prophylaxis for transplantation of HLA-haploidentical
BM grafts. Notably, in the United States, transplantation
of unmanipulated BM from haploidentical related donors
is followed by post-transplantation cyclophosphamide
(100 mg/kg) after reduced-intensity transplant conditioning
(total body irradiation 200 cGy, low-dose cyclophosphamide,
and ﬂudarabine) and GVHD prophylaxis with tacrolimus and
mycophenolate [35]. More recently, 2 reports from Italy that
adopted the approach of transplanting unmanipulated BM
from haploidentical related donors also reported favorable
outcomes [36,37]. One approach incorporated high-
dose post-transplant cyclophosphamide, cyclosporine, and
mycophenolate to a myeloablative transplant conditioning
regimen [36], and the other incorporated a 5-drug GVHD
prophylaxis to myeloablative or reduced-intensity transplant
conditioning regimens [37]. The former report that used
high-dose post-transplant cyclophosphamide demonstrated
adequate recovery of immune function as evidenced by CD4þ
lymphocyte recovery at days þ100 and þ150 post-
transplantation. Data on immune reconstitution are lacking
for the later report.
The effect of HLA mismatching between donor and
recipient are mixed with some reporting relevance. For pa-
tients receiving post-transplantation cyclophosphamide and
reduced-intensity conditioning, increasing HLA mismatch
between donor and recipient was not found toworsen GVHD
or to compromise survival [38]. After myeloablative condi-
tioning, HLA-B mismatching was found to compromise
outcome, but multiple HLA mismatches between donor and
recipient did not have synergistic negative effects on
outcome [39]. It is therefore possible that improved regi-
mens of GVHD prophylaxis have mitigated the negative
impact of HLA mismatching on outcome after T cellereplete,
HLA-haploidentical BM transplantation to the point that
outcomes of such transplants are comparable with those of
transplants from HLA-matched siblings or unrelated donors
[40,41].
NK cells may play a signiﬁcant role in the graft-versus-
tumor effect of HLA-haploidentical transplantation [34],
raising the possibility that donors could be selected to
optimize NK cell alloreactivity to reduce the risk of relapse.
The killer immunoglobulin-like receptor (KIR) genetic locus
on chromosome 19q13.4 encodes a set of receptors on NK
cells for HLA Class I molecules. KIRs can either be stimulatory
or inhibitory to NK cell activation depending on the length of
the receptor’s cytoplasmic tail. Speciﬁc alleles of HLA Class I
Figure 3. Donor selection algorithm. MRD indicates matched related donor; URD, unrelated donor; MURD, HLA-mismatched unrelated donor; DSA, donor-speciﬁc
antibody.
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tion and killing. When donor and recipient are HLA
haploidentical, it is possible that the recipient lacks HLA
molecules for inhibitory KIRs, leading to NK cell alloreactivity
and a graft-versus-leukemia effect. Speciﬁc incompatibilities
in KIR ligands (HLA Class I molecules) between donor and
recipient were associated with a reduced risk of relapse of
acute myeloid leukemia after myeloablative conditioning
and T celledepleted, HLA-haploidentical stem cell trans-
plants [34,42]. However, the presence of T cells in the donor
graft and GVHDmay nullify the beneﬁcial effect of KIR ligand
incompatibility [43]. The presence of speciﬁc stimulatory
KIRs or KIR haplotypes in the donor has been associated with
favorable outcomes after HLA-matched unrelated or
HLA-haploidentical BM transplantation [44-46]. Prospective
clinical trials will ultimately be required to determine
whether the outcome of HLA-haploidentical transplantation
can be improved by selecting donors based on speciﬁc KIR
genes or haplotypes.SUMMARY
Our review of published data support any 1 of 3 following
donor options for the case illustrated in this review:
haploidentical relative, HLA-mismatched unrelated adult, or
UCB. For the case illustrated in the Introduction, we recom-
mend enrolling the patient in the clinical trial (BMT CTN
1101) that randomizes patients to receive BM grafts from a
haploidentical relative or 2 UCB units. Only through the
conduct of well-designed clinical trials can we understand
and appreciate the complexities of donor choices and their
outcome on allogeneic transplantation for hematologic
malignancies. There are no ongoing trials that compare
outcomes after HLA-mismatched adult unrelated donor with
that after related mismatched or UCB transplantation.
The timing of transplantation is critical for a successful
outcome for patients with hematologic malignancy; disease
risk, performance score, and comorbidities are associated
with survival after transplantation. Patients thought to
beneﬁt from transplantation must proceed to this treatment
M. Eapen et al. / Biol Blood Marrow Transplant 20 (2014) 1485e1492 1491in a timely manner. Consequently, in the absence of
HLA-matched sibling, available HLA typings from other
family members (siblings and/or parents) should be
reviewed to determine whether haploidentical related do-
nors are available and an unrelated donor search for either an
adult donor or UCB units should be initiated. Therefore, in-
formation on the 3 alternative donor options are available
when counseling patients for alternative donor trans-
plantation (Figure 3). The data to date support using an
HLA-matched adult unrelated donor (matched at the allele
level at HLA-A, -B, -C, and -DRB1) when such a donor is
available in a timely manner to donate. Barring this, little
evidence supports the superiority of an HLA-mismatched
unrelated donor to a haploidentical relative or UCB units.ACKNOWLEDGMENTS
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